Cite
Cross‐neutralization of RBD mutant strains of SARS‐CoV‐2 by convalescent patient derived antibodies.
MLA
Lou, Yan, et al. “Cross‐neutralization of RBD Mutant Strains of SARS‐CoV‐2 by Convalescent Patient Derived Antibodies.” Biotechnology Journal, vol. 16, no. 11, Nov. 2021, pp. 1–14. EBSCOhost, https://doi.org/10.1002/biot.202100207.
APA
Lou, Y., Zhao, W., Wei, H., Chu, M., Chao, R., Yao, H., Su, J., Li, Y., Li, X., Cao, Y., Feng, Y., Wang, P., Xia, Y., Shang, Y., Li, F., Ge, P., Zhang, X., Gao, W., Song, G., & Du, B. (2021). Cross‐neutralization of RBD mutant strains of SARS‐CoV‐2 by convalescent patient derived antibodies. Biotechnology Journal, 16(11), 1–14. https://doi.org/10.1002/biot.202100207
Chicago
Lou, Yan, Wenxiang Zhao, Haitao Wei, Min Chu, Ruihua Chao, Hangping Yao, Junwei Su, et al. 2021. “Cross‐neutralization of RBD Mutant Strains of SARS‐CoV‐2 by Convalescent Patient Derived Antibodies.” Biotechnology Journal 16 (11): 1–14. doi:10.1002/biot.202100207.